NOVO NORDISK A S (NONOF)

Novo Nordisk is a big Danish drug maker. The company focuses on a few disease areas: diabetes (type 1 and type 2), obesity, bleeding disorders, and hormone deficiencies. It makes insulin, which diabetics need to stay alive. It makes newer drugs that help people lose weight. These are not cure-all treatments. They are drugs people take for years or decades, often for the rest of their lives. That makes them reliable money-makers for the company.

The company is split into two main parts. One part makes and sells insulin and the newer diabetes and obesity drugs. The other part makes blood-clotting treatments for people with hemophilia. Both parts depend on a global supply chain to manufacture medicines in factories, ship them to hospitals and pharmacies, and get them into patients’ hands.

How Novo Nordisk makes money

The core of the business is insulin. Diabetes is common and growing — more than 400 million people worldwide have it. Most people with type 2 diabetes eventually need insulin to control their blood sugar. Type 1 diabetics need it from the start. Novo Nordisk does not own the patent on insulin anymore (that patent expired), but it has dominated the insulin market for decades through brand recognition and the sheer difficulty of switching patients to a new brand.

A person with diabetes gets their insulin from a pharmacy or a hospital. The patient (or their insurance company) pays for it. That money flows back up the supply chain: pharmacy buys from wholesaler, wholesaler buys from Novo Nordisk. The margin the company keeps — the profit on each vial or pen of insulin — is substantial. Insulin is not cheap, and there is not much competition in some markets.

In recent years, Novo Nordisk launched a new class of drugs called GLP-1 receptor agonists. These drugs were originally developed for diabetes, but doctors and patients discovered they also work for weight loss. Drugs like semaglutide (sold as Ozempic for diabetes, Wegovy for weight loss) have become blockbusters. They work better for weight loss than older drugs, they are relatively safe, and they address a market (overweight and obese adults) that is enormous. The company’s weight-loss drugs became so popular that the company struggled to keep up with demand in 2023 and 2024. People could not find the drugs in pharmacies. That shortage pushed prices up and made media headlines.

The hemophilia business is smaller but more stable. Hemophilia is a rare blood-clotting disorder. Patients with hemophilia need regular infusions of clotting factors to prevent bleeds. These treatments are expensive and necessary — a patient cannot skip their infusion without serious risk. Novo Nordisk makes several of these clotting-factor drugs and sells them to hospitals and specialty pharmacies.

The supply chain and the pressures

Novo Nordisk’s supply chain is complex. The company manufactures insulin and other drugs in factories in Denmark, the United States, and other countries. Insulin is made through genetic engineering — bacteria or yeast cells are programmed to produce human insulin, which is then purified. That requires specialized facilities, quality control, and decades of operational experience. It is not easy to build a new insulin factory or to switch production quickly.

Once insulin is made, it needs to be put into pens or vials, packaged, and shipped to wholesalers and pharmacies across the world. This is a logistics problem. Novo Nordisk maintains distribution networks in dozens of countries. Disruptions in shipping, manufacturing, or distribution can create shortages for patients.

Because insulin has been around for a century, the supply chain has settled into a few large manufacturers. Novo Nordisk, Eli Lilly, and Sanofi together make most of the world’s insulin. That concentration means Novo Nordisk has power — it can raise prices and customers have limited alternatives. But it also means the company faces intense regulatory and political pressure. Politicians and patient advocates complain that insulin is too expensive. Regulators in various countries try to cap prices or force generic competition.

The newer obesity drugs have created supply-chain stress. These drugs are so popular that demand has outpaced supply. Novo Nordisk has invested billions to expand manufacturing capacity, but it takes years to build a new pharmaceutical factory and years more to staff and validate it. In the meantime, shortages persist.

What makes Novo Nordisk different

The company has been around for decades and has deep expertise in drugs that people need consistently over their lifetime. Insulin is not a fad drug. Obesity treatment drugs are newer, but they target a large population and early evidence suggests people stick with them. That reliability of demand is valuable in the pharmaceutical industry, where many drugs fail in trials and others have only a small patient population.

Novo Nordisk also owns its manufacturing and distribution in many markets, rather than licensing its drugs to partners. That gives the company more control but also more costs. A smaller competitor might license out its obesity drug to a larger company and avoid the burden of building supply chains, but Novo Nordisk invests in that infrastructure itself.

The company is exposed to diabetes and obesity trends. As the world gets heavier and lives longer, more people develop type 2 diabetes and want weight-loss treatment. That is a tailwind for the company. But it is also reliant on a small number of medicines. If a competitor launches a better obesity drug, or if one of Novo Nordisk’s drugs falls out of favor, the business could face sudden pressure.

Pricing and regulatory risk

Novo Nordisk faces constant criticism over the price of insulin. Patients in the United States pay much more for insulin than patients in Europe or Japan for the same drug. That price gap exists because the United States has less price regulation than other countries. Lawmakers have proposed price caps or requirements to lower insulin prices. If the United States government passes price controls, it would hit Novo Nordisk’s earnings hard — the US market is huge.

Patent cliffs are another risk. Many of Novo Nordisk’s key drugs have patents that will expire in the coming years. When a patent expires, generic competitors can enter the market, and prices usually fall sharply. The company must keep launching new drugs or new formulations to replace the revenue from drugs going generic.

Regulatory approval is always uncertain. A new drug that looks promising in trials can fail at the last stage. A competitor’s drug can be shown to have side effects that shift the market. These risks are inherent to the pharmaceutical industry.

How to think about Novo Nordisk

Novo Nordisk is not a growth company in the sense of a tech startup with explosive revenue expansion. It is a profitable, established pharmaceutical company that makes drugs people need. The supply chain of pharmaceuticals — from manufacturing to distribution to the patient — is global, regulated, and capital-intensive.

The company’s annual report (SEC CIK 0000353278) breaks down revenue by product and by geography. Look at how much of the profit comes from insulin versus newer drugs, and whether obesity-drug demand is holding up. Watch for any commentary on manufacturing capacity expansion or supply constraints. Patent expirations are listed in SEC filings and are key dates to watch — when a major drug goes generic, earnings will fall unless the company has a replacement in hand.

The fundamentals of Novo Nordisk are straightforward: sick people need insulin and weight-loss drugs, the company makes them reliably, and it charges prices the market will bear. That is not exciting, but it is durable. The risks are equally clear: price regulation, patent cliffs, and the emergence of better competitors. Investors in Novo Nordisk are betting that the company can navigate these challenges while the obesity-drug boom runs its course.